XM does not provide services to residents of the United States of America.
D
D

DiaSorin

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Adyen NV, Beazley, Nel ASA

EUROPE RESEARCH ROUNDUP-Adyen NV, Beazley, Nel ASA Aug 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen NV, Beazley and Nel ASA, on Friday. HIGHLIGHTS * Adyen NV ADYEN.AS : TD Cowen raises target price to EUR 1,620 from EUR 1,618 * Beazley BEZG.L : HSBC raises target price to 780p from 665p * Diageo DGE.L : HSBC cuts target price to 3,000p from 3,300p * Nel ASA NEL.OL : Berenberg cuts to hold from buy * ThyssenKrupp Nucera
A
A
B
B
B
C
C
D
D
E
F
F
G
H
I
L
P
P
S
T
V
D
D
F

Euronext, Pearson, Saint-Gobain

EUROPE RESEARCH ROUNDUP- Euronext, Pearson, Saint-Gobain July 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Euronext, Pearson and Saint-Gobain on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : HSBC cuts target price to EUR 1600 from EUR 1900 * Deutsche Boerse AG DB1Gn.DE : JP Morgan raises target price to EUR 198 from EUR 194 * Euronext NV ENX.PA : JP Morgan cuts target price to EUR 107 from EUR 108 * Pearson PSON.L : JP Morgan cut
A
C
C
D
D
E
E
H
H
L
L
P
P
P
R
S
S
S
A
D
J
S

Italy - Factors to watch on July 30

Italy - Factors to watch on July 30 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Chinese President Xi Jinping and Italian Prime Minister Giorgia Meloni discussed the war in Ukraine and the crisis in the Middle East at a meeting in Beijing on Monday, Meloni's office said.
A
B
E
H
I
L
R
A
D
D
F
I
P
I
U

DiaSorin raises 2024 guidance slightly following Q2 results

UPDATE 1-DiaSorin raises 2024 guidance slightly following Q2 results Adds revenue and adj. core profit in paragraph 3-4, shares movement in 5 July 29 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI raised its guidance slightly for 2024 after reporting on Monday a 9% rise in second-quarter adjusted core profit. The company said it now expects revenue growth this year of between 6%-7% compared to previous guidance of 5%-7% growth, and sees its 2024 adjusted core profit margin at abo
D

DiaSorin slightly raises 2024 guidance following Q2 results

DiaSorin slightly raises 2024 guidance following Q2 results July 29 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Monday slightly hiked guidance for 2024, after its second quarter adjusted core profit rose 9% at a constant exchange rate compared to the same period last yea. The company now expects for 2024 a growth in revenue excluding Covid between 6%-7% compared to previous guidance of 5%-7% growth, and sees its 2024 adjusted core profit margin at about 33% compared to a pr
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.